Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, randomised, double-blind, placebo-controlled, multi-centre study to investigate the impact of Diamyd on the progression of diabetes in patients newly diagnosed with type 1 diabetes mellitus.

Next Previous
X
Search
Trial Profile

A phase II, randomised, double-blind, placebo-controlled, multi-centre study to investigate the impact of Diamyd on the progression of diabetes in patients newly diagnosed with type 1 diabetes mellitus.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GAD65 vaccine (Diamyd) (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Diamyd Medical AB

    • Most Recent Events

    • 05 Aug 2020 Results (n=521) of an analysis from three clinical studies: NCT00435981, NCT00529399 and NCT00723411 assessing efficacy of GAD-specific immunotherapy in presence of the GAD and insulin antibody-associated HLA haplotypes DR3-DQ2 and DR4-DQ8 published in the Diabetologia
    • 12 Jul 2011 EudraCT reports actual initiation date 13 Dec 2004, actual end date is 13 Dec 2011.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top